Xiaoxing Wang

Xiaoxing Wang

Auto-generated profile, based on publicly available information

Xiaoxing Wang

Department of Pharmacy, China-Japan Friendship Hospital, Beijing, 100029, China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2020 in Current Drug Metabolism
Verified
Journal Article
Closed access
PDF file
XWXiaoxing Wang
Xiaoxing Wang
WDWenwen Du
Wenwen Du
XZXianglin Zhang
Xianglin Zhang
PLPengmei Li
Pengmei Li
Background: The anti-CD20 antibody rituximab, which promotes the selective depletion of CD20 positive B cells, was the first targeted therapy that was approved for the treatment of B-cell malignancies, and it is now widely prescribed in both malignant and non-malignant, immune-related diseases. However, the cause of its various clinical responses in certain diseases, have not been clearly elucidated. The variabilities in inter-individual pharmacokinetic and the emerging evidence of the relationships between pharmacokinetic and pharmacodynamic may provide a better understanding of this drug.Methods: We searched and summarized the latest published articles on rituximab pharmacokinetic profiles and the pharmacokinetic/pharmacodynamic models in different patient populations, including B-cell malignancies, rheumatoid arthritis, ANCA-associated vasculitis, and glomerular kidney diseases.Results: Most pharmacokinetic data are drawn from clinical studies in oncology clinical practice. Body weight, gender, and antigen-related factors are proven to be the key factors affecting rituximab pharmacokinetics. In addition, the positive exposure-response relations were reported, which provide encouraging evidence for individualized therapies. While in immune disorders, especially in the off-labeled indications, pharmacokinetic studies are quite limited. Compared with that in B-cell malignancies, the differences in the pharmacokinetic parameters may be attributed to the different pathogeneses of diseases, mechanisms of action and dosing strategies. However, the correlation between drug exposure and clinical outcomes remains unclear.Conclusion: Here, we provide an overview of the complexities associated with rituximab pharmacokinetics and pharmacodynamics in different diseases. Although many influencing factors need to be verified in future studies, a better understanding of the relationships between pharmacokinetic and pharmacodynamic may assist in optimizing rituximab clinical practice.

1 January 2026 in Journal of Clinical Pharmacy and Therapeutics
Verified
Journal Article
Open access
DZDan Zhang
Dan Zhang
WDWenwen Du
Wenwen Du
WQWei Qin
Wei Qin
BLBo Li
Bo Li
PLPengmei Li
Pengmei Li
WCWenqian Chen
Wenqian Chen
Background: Voriconazole (VCZ) served as primary therapy for invasive aspergillosis in lung transplant recipients. However, VCZ‐induced hepatotoxicity emerged as a frequent adverse effect that critically compromised postoperative management and complication prevention in this vulnerable population. Methods: We performed population pharmacokinetic/pharmacodynamic (PK/PD) modeling using nonlinear mixed‐effects methodology. The analysis included a one‐compartment PK model with alkaline phosphatase (ALP) as the primary hepatotoxicity biomarker. Monte Carlo simulations assessed the effects of dosing regimens on ALP dynamics across various covariate scenarios. Results: The final PK/PD model indicated an apparent systemic clearance of 3.09 L/h and a central volume of 80.31 L. The exposure–response relationship was described using an indirect response model, with the pharmacological effect linked to increases in ALP levels. The maximum drug effect (E max ) was 188.78. The rate constant for psoriatic plaque production (K in ) was 0.31/day, while the rate for plaque loss (K out ) was 0.53/day. Creatinine clearance (CrCL) was identified as a key covariate for apparent clearance, while weight and tacrolimus (TAC) trough level were significant for Emax. The average probability of target attainment for optimized regimens reached 50.2% across all covariate combinations. Clinical simulations identified 100 mg twice daily (bid) as the optimal maintenance dose for hepatotoxicity prevention. Weight‐based dose reduction was recommended for recipients below 50 kg, with stringent therapeutic drug monitoring of TAC concentrations. Conclusion: Our population PK/PD model provides clinically actionable guidance for VCZ dose optimization, particularly for underweight lung transplant recipients on maintenance therapy. The model effectively predicts and prevents VCZ‐induced hepatotoxicity while maintaining therapeutic efficacy.

6 December 2023 in Pulmonary Pharmacology & Therapeutics
Verified
Journal Article
Closed access
XWXiaoxing Wang
Xiaoxing Wang
WDWenwen Du
Wenwen Du
DZDan Zhang
Dan Zhang
WCWenhui Chen
Wenhui Chen
XZXianbo Zuo
Xianbo Zuo

28 April 2021 in Journal of Nanomaterials
Verified
Journal Article
Open access
PDF file
XHXingzhen Hu
Xingzhen Hu
XWXiaoxing Wang
Xiaoxing Wang
WMWeisi Mao
Weisi Mao
LYLingling Ying
Lingling Ying
ZHZongzhang Huang
Zongzhang Huang
Objective. Rotator cuff tear (RCT) accounts for 50% of shoulder injuries, leading to chronic pain and disability in the upper extremity. The study is conducted to investigate the association between resonance imaging (MRI) classifications of patients with RCT and different shoulder outcome scores. Methods. From September 2018 to October 2019, 112 patients underwent shoulder MRI at our institution and selected as eligible study subjects according to inclusion and exclusion criteria. Among these 112 patients, 69 cases had confirmed history of shoulder trauma and 43 cases were due to chronic shoulder joint pain. The shoulder function of patients was evaluated by University of California Los Angeles Shoulder (UCLA) score, Constant-Murley score, Shoulder Pain and Disability Index (SPADI), and simple shoulder test (SST). Results. Among the 112 patients, there were 34 cases, 58 cases, and 20 cases with MRI classifications at grades I, II, and III, respectively. There was no significant difference in the injured tendons in patients with different MRI classifications ( ). The injury at the supraspinatus was more common. The scores of UCLA, Constant-Murley, and SST in patients with MRI grading at grade I were significantly higher than those at grades II and III ( ), which were significantly higher in patients at grade II than those at grade III ( ). SPADI score in patients with MRI grading at grade I was significantly lower than that at grades II and III ( ), while there was no significant difference in SPADI score between patients at grades II and III ( ). MRI classifications were negatively correlated with scores of UCLA, Constant-Murley, and SST ( ). There was no significant correlation between MRI grade and SPADI scores ( ). Conclusion. The supraspinatus tendon injury is more common in patients with RCT. MRI classifications were negatively correlated with scores of UCLA, Constant-Murley, and SST.